Results 41 to 50 of about 471 (127)

Management of clinical infections of Escherichia coli by new β-lactam/ β-lactamase inhibitor combinations

open access: yesIranian Journal of Microbiology, 2022
Background and Objectives: Escherichia coli (E. coli) is an important member of Enterobacteriaceae family involved in severe infections. The increased rate of resistance towards different classes of antibiotics limits their treatment options. The aim of
Ashraf Ahmed Kadry   +2 more
doaj   +1 more source

Evaluating the health economic impact of cefepime/enmetazobactam in complicated urinary tract infections in the German setting: a cost analysis from payer perspective. [PDF]

open access: yesInfection
Objectives: Complicated urinary tract infections (cUTIs) are ubiquitous, associated with healthcare resources, and demand effective antibiotic treatment to prevent clinical failure and relapse.
Röder J   +8 more
europepmc   +2 more sources

In vitro activity of cefepime/zidebactam against sulbactam/durlobactam-susceptible and -resistant Acinetobacter baumannii clinical isolates. [PDF]

open access: yesJ Antimicrob Chemother
Objectives: To evaluate the in vitro activity of cefepime in association with a β-lactamase inhibitor (enmetazobactam) or β-lactam enhancer (BLE), zidebactam, against carbapenem-resistant Acinetobacter baumannii (CRAB) strains susceptible or resistant to
Tascini C   +3 more
europepmc   +2 more sources

<i>In vitro</i> activity of cefepime/zidebactam against <i>Klebsiella pneumoniae</i> carrying <i>bla</i> <sub>KPC</sub> variants conferring resistance to ceftazidime/avibactam. [PDF]

open access: yesJAC Antimicrob Resist
Objectives: Resistance to ceftazidime/avibactam among KPC-producing Klebsiella pneumoniae (KPC-Kp) is often due to mutations within the bla KPC gene, determining a widespread occurrence of novel variants.
Tascini C   +3 more
europepmc   +2 more sources

In vitro activity of cefiderocol, cefepime/enmetazobactam, cefepime/zidebactam, eravacycline, omadacycline, and other comparative agents against carbapenem-non-susceptible Pseudomonas aeruginosa and Acinetobacter baumannii isolates associated from bloodstream infection in Taiwan between 2018–2020

open access: yesJournal of Microbiology, Immunology and Infection, 2022
Background/purpose: This study aimed to investigate the in vitro susceptibilities of carbapenem-non-susceptible Pseudomonas aeruginosa (CNSPA) and Acinetobacter baumannii (CNSAB) isolates to cefiderocol, novel β-lactamase inhibitor (BLI) combinations ...
Po-Yu Liu   +23 more
doaj   +1 more source

Cefepime/Enmetazobactam. [PDF]

open access: yesHosp Pharm
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees.
Staten AR, Baker DE.
europepmc   +3 more sources

Zwitterionic Penicillin‐Derived Sulfone Inhibitor for Combating β‐Lactamase‐Mediated Antibiotic Resistance

open access: yesChemMedChem, Volume 21, Issue 9, 14 May 2026.
Combining enhanced permeability strategies with (2‐pyridyl)methylene substitution in the sulbactam scaffold led to a novel β‐lactamase inhibitor to combat β‐lactamase‐mediated resistance to β‐lactam antibiotics. The studies presented highlight the potential of compound 3 as a next‐generation β‐lactamase inhibitor for combating infections caused by ...
Diana Rodríguez   +4 more
wiley   +1 more source

Comparative Analysis of Antimicrobial Resistance Profiles in Enterobacteriaceae Isolates From Outpatient Carriages and Clinical Infections in an Urban Setting

open access: yesBioMed Research International, Volume 2026, Issue 1, 2026.
Background The emergence and spread of multidrug‐resistant Enterobacteriaceae (MDR‐E) in community and hospital settings constitute a major public health challenge, particularly in densely populated urban areas. Although antimicrobial resistance among clinical isolates has been repeatedly studied, resistance profiles of intestinal carriage strains ...
Kobina Amandzé Adams Kofi   +8 more
wiley   +1 more source

P100 Validation of cefepime/enmetazobactam on Bruker AST devices [PDF]

open access: yesJAC Antimicrob Resist
Abstract Objectives To evaluate the feasibility and manufacturing robustness of integrating the novel β-lactam/β-lactamase inhibitor combination cefepime/enmetazobactam (FEP/META) which has been approved by FDA, EMA and MHRA, into Bruker’s antimicrobial susceptibility testing (AST) devices ...
Ward, Jon   +5 more
europepmc   +2 more sources

A Review of In Silico and In Vitro Approaches in the Fight Against Carbapenem‐Resistant Enterobacterales

open access: yesJournal of Clinical Laboratory Analysis, Volume 39, Issue 9, May 2025.
This review highlights computational approaches for discovering antimicrobials against carbapenem‐resistant Enterobacterales. It outlines methods like pharmacophore modeling, molecular docking, and absorption, distribution, metabolism, and excretion–toxicity (ADMET) analysis, integrated with in vitro assays, to identify and validate potential drugs ...
Muhammad Absar   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy